Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diclofenac/tolperisone controlled release

Next Previous
Drug Profile

Diclofenac/tolperisone controlled release

Alternative Names: Diclofenac SR/tolperisone SR; Diclofenac/tolperisone sustained release; Tolperisone SR/diclofenac SR; Tolperisone/diclofenac controlled release; Tolperisone/diclofenac sustained release

Latest Information Update: 21 Apr 2015

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inventia Healthcare
  • Class Analgesics; Antirheumatics; Antiseptics; Antispasmodics; Muscle relaxants; Nonsteroidal anti-inflammatories; Phenylacetates; Propiophenones; Pyridines; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Neuromuscular blocking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Acute pain

Most Recent Events

  • 21 Apr 2015 No recent reports of development identified - Phase-III for Acute pain in India (PO)
  • 27 Jan 2012 Inventia Healthcare completes a phase III trial in Acute pain (low back pain) in India (CTRI2011-10-002074)
  • 20 Oct 2011 Phase-III clinical trials in Acute pain in India (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top